Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: President Alberto Fernandez earlier this week ordered all but essential workers to stay home and off the streets. But he was forced to amend the list of exceptions after receiving a message from the mother of a 7-year old boy who had recently lost his first tooth. “Dear @alferdez, I need to ask if the tooth fairy is among those exempted from quarantine? Joaquin has lost his first tooth and we don´t know if we should leave him a letter (we can´t find the tooth). We don´t want to cause the tooth fairy problems or for the police to detain him.”  Fernandez reassured the boy an hour later that the tooth fairy was indeed on the official list of exceptions. “@littlekbz Cecilita! The tooth fairy can leave rewards for fallen teeth because he is not under quarantine. But the rest of us are... Joaquin should leave the tooth beneath his pillow and enjoy the prize,” Fernandez wrote on Twitter. Aside from the tooth fairy, Argentina has also exempted key agricultural and export industry workers from the lockdown, and allows people on the streets to buy groceries and medicine, and for urgent medical needs. The country thus far has confirmed 158 cases of coronavirus and four deaths from the disease. Click here for a GRAPHIC on Argentina coronavirus cases
Example Output: Tooth fairy in quarantine? Argentina makes exemption in coronavirus lockdown.

Example Input: Prime Minister Boris Johnson’s top medical adviser, Chris Whitty, said on Wednesday that data on the extent and impact of the outbreak was encouraging but that it was too soon to focus the next phase of the government’s response. “Our view is that it is probably reaching the peak overall,” Whitty said at the government’s daily news conference. “We are not yet at the point where we can say confidently and safely ‘this is now past the peak and we can start thinking very much now about the next phases.’”  So far, more than 12,868 people with COVID-19 have died in British hospitals, though new official data indicates the true death toll could be much larger. Whitty said the daily number of deaths could rise in coming days due reporting lags. The government is widely expected to announce on Thursday that it will extend the most far-reaching restrictions on daily life in Britain’s peacetime history. But Johnson had initially refrained from approving the stringent controls that other European leaders imposed. He later closed down the country when projections showed a quarter of a million people could die in the United Kingdom. The leader of the opposition Labour Party, Keir Starmer, said the prime minister had initially been too slow to impose the lockdown, signalling the political row that is likely to dominate the national discourse for years to come. “I am worried that it looks like we are going to have a higher death rate than any other country in Europe and there will obviously be searching questions about why that has happened,” Starmer told LBC radio. “I did think the government was going too slowly,” Starmer said. “We will have to look back in due course.”  A widespread lockdown came into force on March 23. Prior to that the Conservative government had urged people not to make unnecessary journeys and to cut down on socialising, rather than closing establishments down. But Britons had still packed pubs and restaurants, and even the Cheltenham horse-racing event went ahead, bringing together thousands of punters. Johnson even joked about shaking hands with medical staff during a hospital visit. Starmer, a 57-year-old former prosecutor who won the Labour Party leadership earlier this month, also called on the government to publish its exit strategy from lockdown restrictions. Foreign minister Dominic Raab, who is deputising for Johnson while he recovers from COVID-19, will lead a cabinet meeting on Thursday morning, and in the afternoon chair an emergency response committee meeting to decide on extending the lockdown   The United Kingdom’s hospital death toll from COVID-19 rose by 761 to 12,868 as of 1600 on April 14, the health ministry said. The toll had gone up by 778 the previous day. The official British death toll is the fifth-highest globally after the United States, Italy, Spain and France. The United States has reported more than 28,000 deaths while Italy has reported more than 21,000. Several European countries have announced plans or already begun to relax restrictions, balancing the risk of reversing gains against further damage to battered economies. Starmer said Labour supported extending the measures in Britain but that to “maintain morale and hope”, the public needed to have an idea of what is coming next. Government officials have defended their course of action regarding the start of the lockdown and said it would be a mistake to talk about how to end the lockdown before they were confident the peak had been reached. Amid the doom, though, there were rays of hope. A 106-year-old woman, thought to be the oldest patient in Britain to beat the novel coronavirus, was discharged from hospital. Connie Titchen, born in 1913, had battled suspected pneumonia and COVID-19. A 99-year-old war veteran, Tom Moore, has raised more than 8 million pounds ($10.03 million) for Britain’s health service with a walk around his garden.
Example Output: UK virus outbreak 'probably' peaking, but too soon to ease lockdown.

Example Input: "The story says that the average copayment for a month’s supply of some of the topical NSAID medications is around $30. It would have been nice to include the cost of comparable oral medications. Although the story explains the available evidence comparing topical NSAIDs to oral pain relievers, highlights the limited number of direct comparisons, and carefully states the general consensus of experts, all of this solid reporting is undermined by a focus on personal anecdotal evidence over quantifiable benefits. Indeed, the reporter claims one medication provided immediate relief, a statement at odds with clinical trials that conclude that it usually takes hours for patients to feel the pain-relief effects of topical NSAIDs. The story summarizes the reported side effects of topical NSAIDS. What’s more, the reporter points out that the potential risks in people who have other health problems or are taking other drugs have not been well studied. That insight is something we see too rarely. The story refers to a number of clinical trials and systematic reviews of the evidence. It highlights areas where evidence is lacking or inconclusive. It would have been helpful to point out that in placebo-controlled trials, almost as many people who received the placebo reported pain relief as did those who got the active medication. The story could have mentioned that the systematic review it referred to was published by the Cochrane Collaboration and also the sources of the other clinical trial reports, so that interested readers could more easily locate the original articles. The story does not exaggerate the common pains these drugs are intended to treat, but the personal anecdotes and opinions highlighted at the beginning and ending of the story are unrepresentative of the typical experiences reported by participants in clinical trials and create a powerful impression that is at odds with the evidence. The story includes quotes from several experts and points out that two of them have accepted consulting fees or research support from pharmaceutical companies. The essence of this story is an attempt to compare topical NSAIDs with pills and other pain treatments. As noted above, though, the story does not mention that most people with minor pains feel better after awhile even if they don’t take any pain relief medication. It also should have mentioned that the difference between placebo and active treatment groups in the clinical trials is often slim. The story reports that only three topical NSAIDs (nonsteroidal anti-inflammatory drugs) are approved for sale with a prescription in the United States, while several brands are sold over the counter in Europe. Part of the focus of the story is that NSAIDS have been around for a long time but only recently are being given a more serious scientific reassessment. As the story says, ""But a number of new controlled trials and meta-analyses like Dr. Moore’s suggest that topical Nsaids are as effective as their oral counterparts for treating osteoarthritis in the knee and hand as well as musculoskeletal injuries like soreness and tendinitis."" The story includes several experts and mentions multiple studies."
Example Output:
Topical Gel Catches Up With Pills for Relief